Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index Up 0.40% in November (+6.36% YTD)

Friday, December 14, 2012
Opalesque Industry Update: Hedge funds gained 0.40% in November, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index is up 6.36% year to date.

“In spite of an early month sell-off driven by fiscal cliff fears followed by a mid-month rally fueled by encouraging economic data, hedge funds were able to get through the tumult with a small profit in November,” says Sol Waksman, founder and president of BarclayHedge.

The Barclay European Equities Index led all hedge fund strategies in November with a 1.54% gain. Merger Arbitrage was up 1.17%, the Event Driven Index added 0.83%, and Fixed Income Arbitrage gained 0.75%.

“Europe outperformed the US in November; the MSCI Europe Index gained 2.41 percent versus a gain of 0.58 percent for the S&P 500 Total Return Index,” says Waksman.

“In spite of the uncertainty of a clear path to resolution of the eurozone’s fiscal woes, European equities have managed to gain 12.8% this year.”

Only three of the 18 hedge fund strategies tracked by BarclayHedge had losses in November. The Equity Short Bias Index was down 2.34%, Technology lost 0.43%, and Global Macro slid 0.31%.

Year to date, Healthcare & Biotechnology is up 12.93%, and Distressed Securities have gained 10.00%, European Equities are up 8.55%, and Fixed Income Arbitrage has gained 8.47%.

Equity Short Bias is the only losing hedge fund strategy in 2012. After 11 months, Short Bias is down 19.34%. This is its biggest loss since 2003, when the Index was down 23.95% at year-end.

“Upward trending equity markets in 2012 have dealt short sellers a difficult hand to play this year,” says Waksman.

“The dramatic 10.04 percent jump in the Equity Short Bias Index in May was not enough to offset seven months of significant losses.”

The Barclay Fund of Funds Index gained 0.40% in November, and is up 3.40% in 2012.

BarclayHedge

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for